My name is Jennifer Chain, but you can call me Jenny. Originally from Amarillo, Texas, I now reside in Norman, Okla., with my husband of more than 20 years and our two teenage sons. My expertise is specialized in allogeneic cellular starting materials for biotherapies by assisting both nonprofit and for-profit collection centers in establishing and expanding their collection programs for biotherapy research, development and manufacturing.
I am here to support cell therapy companies with their starting material procurement programs by defining donor and product specifications, developing tests to identify ideal donors and writing processing protocols. I currently serve as a contract project manager for a biologics contract development and manufacturing organization (CDMO) and contribute to various projects for different organizations within the cell and gene therapy sector.
I joined AABB in 2017 and attended my first AABB Annual Meeting that year in San Diego. As a newcomer to blood banking and cell therapy, I made it a point to connect with as many professionals in the field as possible. During the meeting, I expressed my interest in joining AABB committees and offering my expertise as a consultant. Shortly after, I was invited to join the AABB Cellular Therapies Standards Committee, where I gained valuable insights into cell therapy by contributing to the 9th and 10th editions of the Standards for Cell Therapy Services. In the fall of 2018, I was elected to the Cellular Therapies Subsection Coordinating Committee (CTSCC) and initially led the Novel Therapies Subsection. Later, I co-led the merged Current and Emerging Topics (CT-CET) subsection. In 2024, I was elected as the secretary of the CTSCC. Since 2018, I have actively participated in a variety of committees and working groups. I have also delivered talks and directed education sessions at annual meetings and for eCasts.
When the CABP exam was first offered in 2022, I seized the opportunity to validate my expertise in biotherapies by taking the exam. I was proud to be in the first cohort to receive this certification.
I earned my PhD in immunology, specializing in T cell development, function and senescence. Early in my career, I focused on gamma delta T cells (I loved them before they were cool). Throughout my 27-year career as a scientist, I developed numerous tools and methods and conducted R&D work to create new products and services. Method optimization and product development are among my key areas of expertise.
In 2016, I began expanding my knowledge and experience in blood banking and cell therapy. I assisted my organization in developing cryopreservation, testing and manufacturing protocols and created new blood-based products to support the biotherapies field. For three years, I served as the director of my organization’s allogeneic starting materials collection program, where I concentrated on donor recruitment for cell therapy collections and provided customer service to companies needing starting materials and other blood products. I facilitated significant program growth and solidified my expertise in donor recruitment and characterization for cell therapy products.
I began my consulting journey in 2016, leaving my role at a start-up biotech company where I focused on research and development for new diagnostic testing platforms. I wanted to leverage my extensive expertise in immunology, scientific writing, and method and product development. I assisted numerous clients with grant writing, staff training, laboratory work and product development.
In early 2024, I returned to consulting, this time highlighting my expertise in biotherapies, project management and cellular starting material program development. In that time, I helped six centers with their leukopak collection programs and supported other organizations in achieving their goals in the cell therapy space. What I enjoy most about consulting is the opportunity to use all of my skills—sometimes in traditional ways and sometimes in innovative ways. My clients appreciate the value I bring, which motivates me to be the best consultant I can be.
I am very grateful to be working as a consultant for AABB. Around the time I became available as a consultant, AABB was developing study materials for the CABP exam. I was asked to create some of the CABP boot camp videos that were released in advance of the 2024 AABB Annual Meeting. I developed presentations for Domain 2: Biotherapies Science & Ethics and Domain 5: Manufacturing Biotherapies. Additionally, I reviewed and edited some of the other domain presentations.
I was excited to be part of this project and to contribute my expertise to the development of these educational materials, helping future test takers prepare for the CABP exam. This experience also allowed me to deepen my knowledge of biotherapies through developing and reviewing these presentations.
After spending about 18 years as a bench scientist in immunology, I transitioned into the field of blood and biotherapies. It was the perfect time for me to broaden my expertise and find new ways to contribute to scientific advancement. Joining AABB was the best decision I made to achieve this goal. I gained invaluable knowledge from my fellow committee and subsection members, which enhanced my skills and helped shape me into the scientist and consultant I am today.
I highly recommend getting involved with AABB to anyone new to the field, whether you're just starting your career or looking for new ways to advance it. The field of biotherapies is continuously growing, and there are numerous opportunities to apply experience from traditional scientific and technical fields to biotherapies. Your unique skills and expertise will only serve to improve the field further.
Over the past year, I have had the opportunity to enhance my professional experience in project management and process improvement. I am excited to solidify this expertise by obtaining certifications in Project Management and Six Sigma in 2025, and I look forward to applying these skills in my current and future work.
I am never short of ideas of how to improve the cellular starting material space, and I am excited to put some of these ideas into practice in 2025.
PREVIOUS STORY
Volunteer Spotlight: Justin Halls, MD, MPHBACK TO ISSUE
April 2025Transfusion is AABB’s scholarly, peer-reviewed monthly journal, publishing the latest on technological advances, clinical research and controversial issues related to transfusion medicine, blood banking, biotherapies and tissue transplantation. Access of Transfusion is free to all AABB members.
Learn More About Transfusion JournalKeep abreast of what's happening in the field of biotherapies with CellSource - AABB's monthly update on the latest biotherapies news.
To submit news about the blood and biotherapies field to AABB, please email news@aabb.org.
President
Meghan Delaney, DO, MPH
Chief Executive Officer
Debra Ben Avram, FASAE, CAE
Chief Communications and Engagement
Officer Julia Zimmerman
Director of Marketing and Communications
Jay Lewis, MPH
Managing Editor
Kendra Y. Mims, MFA
Senior Communications Manager
Drew Case
AABB News
(ISSN 1523939X) is published monthly, except for the combined November/December issue for the members of AABB; 4550 Montgomery Avenue; Suite 700 North Tower; Bethesda, MD 20814.
AABB is an international, not-for-profit association representing individuals and institutions involved in transfusion medicine, cellular therapies and patient blood management. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety.
+1.301.907.6977
Email: news@aabb.org
Website: www.aabb.org
Copyright 2025 by AABB.
Views and opinions expressed in AABB News are not necessarily endorsed by AABB unless expressly stated.
Notice to Copiers: Reproduction in whole or part is strictly prohibited unless written permission has been granted by the publisher. AABB members need not obtain prior permission if proper credit is given.